Some of the novel techniques include, using receptor-mediated transcytosis to deliver nanoparticles [187], cell-penetrating peptide conjugated adeno-associated viruses (AAVs) to deliver novel gene therapies [188], organic cation transporters 1 and 2 (Oct1/Oct2) to deliver novel stroke therapeutics [189], intranasal delivery methods [190], cell therapies [191] and focused ultrasound (FUS) in conjunction with gas-filled microbubble contrast agents [192]. This evidence concerns the gene SLC22A1 and Stroke.